Home > Boards > US Listed > Medical - Healthcare > Gilead Sciences, Inc. (GILD)

$gild $72.34 down -2.42 (-3.24%)

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Taurus69 Member Profile
Member Level 
Followed By 170
Posts 24,548
Boards Moderated 165
Alias Born 08/30/12
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 10/23/2020 5:13:26 PM
Gilead Sciences Completes Acquisition of Immunomedics, Inc. Business Wire - 10/23/2020 9:15:00 AM
Covid-19 Drug Remdesivir Fully Approved by FDA Dow Jones News - 10/22/2020 6:39:00 PM
FDA Approves Gilead Sciences' Remdesivir Treatment for Covid-19 Dow Jones News - 10/22/2020 5:01:00 PM
U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19 Business Wire - 10/22/2020 4:02:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/22/2020 12:35:09 PM
Anthony Welters Joins Gilead Sciences’ Board of Directors Business Wire - 10/22/2020 12:15:00 PM
In Pursuit of the Elusive Drug — the Billion-Dollar Blockbuster NetworkNewsWire - 10/22/2020 8:45:00 AM
Gilead Sciences On Pace for Lowest Close Since October 2013 -- Data Talk Dow Jones News - 10/21/2020 1:07:00 PM
Gilead Announces New Data on Biktarvy® for the Treatment of HIV in Black Americans Business Wire - 10/21/2020 7:01:00 AM
Gilead Presents New Data from Antiviral Development Programs at IDWeek 2020 Business Wire - 10/19/2020 8:30:00 AM
WHO-Backed Study Finds No Remdesivir Benefit for Hospitalized Covid-19 Patients -- Update Dow Jones News - 10/16/2020 9:44:00 PM
WHO-Backed Study Finds No Remdesivir Benefit for Hospitalized Covid-19 Patients Dow Jones News - 10/16/2020 6:21:00 PM
Gilead's Kite Says CHMP Adopts Positive Opinion for Lymphoma Drug Dow Jones News - 10/16/2020 8:33:00 AM
European CHMP Adopts Positive Opinion for Kite’s KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Business Wire - 10/16/2020 7:28:00 AM
Gilead Sciences to Release Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 Business Wire - 10/14/2020 4:01:00 PM
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for Immunomedics Tender Offer Business Wire - 10/14/2020 8:30:00 AM
Study of Eli Lilly Covid-19 Drug Paused Due to Safety Concern -- Update Dow Jones News - 10/13/2020 8:16:00 PM
Study of Eli Lilly Covid-19 Drug Paused Due to Safety Concern -- Update Dow Jones News - 10/13/2020 5:52:00 PM
Study of Eli Lilly Covid-19 Drug Paused Due to Safety Concern Dow Jones News - 10/13/2020 3:59:00 PM
Gilead, Galapagos See Sustained Efficacy, Safety for Filgotinib Dow Jones News - 10/12/2020 10:06:00 AM
Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction & Maintenance of Remission in Moderately & Severely Active Ul... Business Wire - 10/12/2020 9:15:00 AM
Final Results of National Institute of Allergy & Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medi... Business Wire - 10/8/2020 5:05:00 PM
Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury® (remdesivir) Business Wire - 10/8/2020 3:00:00 AM
Trump Symptom-Free for 24 Hours, Says White House Doctor--3rd Update Dow Jones News - 10/7/2020 8:45:00 PM
Taurus69 Member Level  Tuesday, 05/19/20 11:36:30 PM
Re: None
Post # of 4601 
$gild $72.34 down -2.42 (-3.24%)

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences